TY  - JOUR
AU  - Martínez-Cuadrón, David
AU  - Gil, Cristina
AU  - Serrano, Josefina
AU  - Rodríguez, Gabriela
AU  - Pérez-Oteyza, Jaime
AU  - García-Boyero, Raimundo
AU  - Jiménez-Bravo, Santiago
AU  - Vives, Susana
AU  - Vidriales, María Belén
AU  - Lavilla, Esperanza
AU  - Pérez-Simón, José A
AU  - Tormo, Mar
AU  - Colorado, Mercedes
AU  - Bergua, Juan
AU  - López, Juan A
AU  - Herrera, Pilar
AU  - Hernández-Campo, Pilar
AU  - Gorrochategui, Julián
AU  - Primo, Daniel
AU  - Rojas, Jose Luis
AU  - Villoria, Jesús
AU  - Moscardó, Federico
AU  - Troconiz, Iñaki
AU  - Linares Gómez, María
AU  - Martínez-López, Joaquín
AU  - Ballesteros, Joan
AU  - Sanz, Miguel
AU  - Montesinos, Pau
AU  - Spanish PETHEMA group
PY  - 2018
DO  - 10.1016/j.leukres.2018.11.006
UR  - http://hdl.handle.net/10668/13223
T2  - Leukemia research
AB  - Complete remission (CR) after induction therapy is the first treatment goal in acute myeloid leukemia (AML) patients and has prognostic impact. Our purpose is to determine the correlation between the observed CR/CRi rate after idarubicin (IDA) and...
LA  - en
KW  - Acute myeloid leukemia
KW  - Clinical correlation
KW  - Complete remission
KW  - Ex vivo assay
KW  - Pharmacological profile
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Bone Marrow
KW  - Cytarabine
KW  - Drug Monitoring
KW  - Female
KW  - Humans
KW  - Idarubicin
KW  - Kaplan-Meier Estimate
KW  - Leukemia, Myeloid, Acute
KW  - Male
KW  - Middle Aged
KW  - Precision Medicine
KW  - Prognosis
KW  - ROC Curve
KW  - Remission Induction
KW  - Treatment Outcome
KW  - Workflow
KW  - Young Adult
TI  - A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients.
TY  - research article
VL  - 76
ER  -